Financial Status - Recursion had $755 million in cash at the end of 2025, projecting runway through the end of 2027[18] - The company anticipates a cash burn of less than $390 million in 2026[39] Pipeline and Platform - Recursion has approximately 5 wholly-owned programs in clinical development and around 15 in discovery[17] - The company's platform has generated over $500 million in upfront and milestone payments[17] - Recursion's supercomputer holds ~65PB of data, including 40PB of proprietary data[45] Partnerships - Sanofi has achieved 4 milestones using AI-designed molecules[27] - Roche and Genentech have delivered 6 AI-powered biology maps[27] - Potential Roche and Genentech and Sanofi milestones per small molecule program is >$300M[17] Clinical Program (REC-4881) - In a study, 75% of evaluable patients with FAP responded to REC-4881 with a 43% median reduction in polyp burden at Week 13[68] - At Week 25, 82% of evaluable patients responded to REC-4881, with 73% achieving durable ≥30% reductions and a 53% median polyp burden reduction[71] - Approximately 87% of untreated FAP patients experienced an annual increase in polyp burden, averaging a 60% increase annually[57, 62]

Group 1 - Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has shown strong performance, with a 6.81% increase in stock price, closing at $4.86, as investors anticipate business updates from upcoming conferences [1] - The company's president and CEO, Najat Khan, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference and the 28th Annual Needham Growth Conference [2] - Investors are particularly interested in updated guidance regarding earnings performance for 2025, pipeline updates, and the outlook for 2026 [3] Group 2 - JPMorgan has upgraded Recursion Pharmaceuticals to "overweight" from "neutral" and raised its price target from $10 to $11, indicating increased confidence in the stock [3] - The upgrade follows positive results from the clinical trial of REC-4881, a therapy candidate for Familial Adenomatous Polyposis, which is projected to generate $1 billion in sales in the U.S. [4]

Core Viewpoint - The clean energy sector demonstrated resilience in 2025 despite challenges from fossil fuel prioritization, with expectations for continued growth in 2026 driven by ongoing transformations in energy and technology [1][2]. Industry Summary - The S&P Global Clean Energy Transition index increased by 46% in 2025, significantly outperforming the broader S&P 500, which rose by 16% [1]. - The clean energy transformation is anticipated to reshape markets such as infrastructure and transportation, leading to new growth opportunities for companies involved in this transition [3]. Company Insights - MYR Group (Ticker: MYRG) reported a 53% return in 2025 and is viewed as a strategic investment in the electrical infrastructure sector, expected to benefit from rising demand due to the AI boom [4][5]. - Recursion Pharmaceuticals (Ticker: RXRX) experienced a -44% return in 2025 but is recognized for its commitment to sustainability. The company is expected to leverage AI advancements in biotechnology and pharmaceuticals, making it a stock to watch [6].

Core Insights - Recursion, a clinical stage TechBio company, focuses on decoding biology to significantly enhance lives [1] - The CEO, Najat Khan, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 [1] - The company will also participate in the 28th Annual Needham Growth Conference on January 16, 2026 [1] Company Overview - Recursion is headquartered in Salt Lake City and is a founding member of BioHive, a collective for the Utah life sciences industry [2] - The company has additional offices in Montréal, New York, London, and the Oxford area [2] - Recursion utilizes a platform called Recursion OS, which generates one of the largest proprietary biological and chemical datasets globally [1] - The company employs advanced machine-learning algorithms to identify trillions of relationships in biology and chemistry, free from human bias [1] - Recursion conducts millions of wet lab experiments weekly and operates one of the most powerful supercomputers in the world to advance medical research [1]

Core Insights - Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is recognized as one of the top AI stocks to buy, with JPMorgan upgrading its rating from Neutral to Overweight and increasing the price target to $11 from $10 following positive trial results for its MEK 1/2 inhibitor, REC-4881 [1][3] Group 1: Clinical Trial Results - The TUPELO trial demonstrated a 43% median reduction in total polyp burden after 12 weeks of treatment, with 75% of evaluable patients showing reductions [2] - Notably, 82% of patients maintained stable decreases 12 weeks post-treatment, achieving a median reduction of 53% from baseline [2] Group 2: Market Potential and Financial Projections - JPMorgan projects peak sales for REC-4881 in the U.S. to exceed $1 billion, with a 60% probability of success [3] - The company has secured over $500 million in milestone payments from pharmaceutical agreements, reinforcing the viability of its AI-driven pipeline [3] Group 3: Strategic Positioning - Recursion Pharmaceuticals is leveraging artificial intelligence and machine learning to expedite drug discovery, particularly targeting rare diseases and oncology [4] - Factors such as expanding patient populations, improved penetration rates, and pricing strategies may provide additional growth opportunities for the company [4]

Core Insights - Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is recognized as one of the 12 best genomics stocks to invest in [1] Group 1: Investment Activity - Cathie Wood's ARK Investment purchased 755,000 shares of Recursion Pharmaceuticals on December 19, 2025 [2] Group 2: Analyst Ratings and Market Potential - JPMorgan upgraded Recursion Pharmaceuticals from Neutral to Overweight, raising the price target from $10 to $11, citing the effectiveness of REC-4881 in treating familial adenomatous polyposis [3] - The addressable market for REC-4881 is larger than previously anticipated, with JPMorgan estimating a 60% chance of success and peak revenues exceeding $1 billion [4] - Early anti-tumor effectiveness of the CDK7 inhibitor REC-617 in platinum-resistant ovarian cancer has also been noted by JPMorgan [4] Group 3: Financial Forecast - The company has maintained its 2025 expense forecast at less than $450 million, excluding partnership inflows, and the 2026 forecast at less than $390 million [5] - Recursion Pharmaceuticals expects its cash position to support operations until the end of 2027 without requiring additional funding [5]

Wall Street is ending 2026 on a generally positive note, with the benchmark S&P 500 Index set to finish the year at a 17% return rate. All eyes are now on technology titans like Nvidia, Microsoft, Alphabet, and Amazon, which have dominated the headlines in 2025, and for good reason.By and large, big technology stocks have outperformed the broad U.S. market in 2025, fueled by strong earnings and momentum in key areas like semiconductors and AI-related companies, with the Nasdaq-100 Index up 19.6% year to dat ...

Company Overview - Recursion Pharmaceuticals (RXRX) is a clinical-stage biotechnology company based in Salt Lake City, focusing on industrializing the drug discovery process through a combination of biological analysis, chemical expertise, advanced automation, data science, and engineering innovations [3] - The company has a market capitalization of $2.3 billion and aims to leverage cutting-edge technology and large datasets to advance medical research [3] Stock Performance - Over the past year, RXRX's stock has decreased by 37.6%, with a further decline of 9.7% in the last six months, currently trading nearly 65% below its peak of $12.36 in February [2][4] - The stock trades at approximately 37.17 times forward sales, which is a premium compared to the broader biotech sector but below its historical average, indicating tempered optimism [8] Financial Results - In Q3, Recursion reported revenue of $5.2 million, a significant drop from $26.1 million in the same quarter the previous year, missing Wall Street expectations [9] - Research and development expenses increased to $121.1 million from $74.6 million, driven by the acquisition of rights to REC-102 and the integration following a business combination with Exscientia [10] - The net loss widened to $162.3 million from $95.8 million, with a per-share loss of $0.36, which was below analyst forecasts [11] Analyst Sentiment - Analysts project revenue of approximately $61.6 million for fiscal 2025, with losses expected to narrow by 5.3% year-over-year to -$1.60 per share [13] - J.P. Morgan upgraded RXRX's stock rating to "Overweight" from "Neutral" and set a price target of $11, reflecting confidence in the company's potential [14][15] - The consensus rating for RXRX is "Moderate Buy," with an average price target suggesting a potential upside of 60.6% [16] Clinical Developments - Recent clinical trial data for REC-4881, an experimental treatment for familial adenomatous polyposis, showed meaningful efficacy, which has contributed to a shift in sentiment towards the stock [15] - The drug is viewed as having blockbuster potential, with a 60% probability of successful commercialization [15] Market Position and Future Outlook - The company is positioned at a crossroads, with improving clinical momentum, a solid cash cushion of $667.1 million as of September 30, 2025, and growing analyst support [12][17] - However, technical signals remain soft, and ongoing losses suggest a cautious approach is warranted, indicating that RXRX may not be ready for a rapid recovery yet [18]

Group 1 - Nvidia's related stocks experienced a collective surge, with NEBIUS (NBIS.US) rising over 6%, Applied Digital (APLD.US) increasing over 5%, and Recursion Pharmaceuticals (RXRX.US) up over 4.8% [1] - CoreWeave (CRWV.US) also saw an increase of over 4.8%, while Arm Holdings (ARM.US) rose by over 1.5%, and Wenyan Zhixing (WRD.US) increased by over 1.2% [1] - Nvidia (NVDA.US) itself saw a rise of 1.25% [1] Group 2 - Reports indicate that Nvidia plans to begin the first deliveries of its H200 artificial intelligence chips to China by mid-February next year [1]

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! AI is eating the world—and the machines behind it are ravenous. Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink. Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and b ...